Literature DB >> 10658622

The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease.

B Mirza1, H Hadberg, P Thomsen, T Moos.   

Abstract

Virtually any neurological disorder leads to activation of resident microglia and invasion of blood-borne macrophages, which are accompanied by an increase in number and change in phenotype of astrocytes, a phenomenon generally termed reactive astrocytosis. One of the functions attributed to activation of astrocytes is thought to involve restoration of tissue damage. Hitherto, the role of astrocytes in the inflammatory reaction occurring in Parkinson's disease has not received much attention. In the present study, we examined the inflammatory events in autopsies of the substantia nigra and putamen from Parkinson's disease patients using age-matched autopsies from normal patients as controls. In the substantia nigra, activation of microglia was consistently observed in all Parkinson's disease autopsies as verified from immunohistochemical detection of CR3/43 and ferritin. Activation of resident microglia was not observed in the putamen. No differences were observed between controls and Parkinson's disease autopsies from the substantia nigra and putamen, in terms of distribution, cellular density or cellular morphology of astrocytes stained for glial fibrillary acidic protein or metallothioneins I and II, the latter sharing high affinity for metal ions and known to be induced in reactive astrocytes, possibly to exert anti-oxidative effects. Together, these findings indicate that the inflammatory process in Parkinson's disease is characterized by activation of resident microglia without reactive astrocytosis, suggesting that the progressive loss of dopaminergic neurons in Parkinson's disease is an ongoing neurodegenerative process with a minimum of involvement of the surrounding nervous tissue. The absence of reactive astrocytosis in Parkinson's disease contrasts what follows in virtually any other neurological disorder and may indicate that the inflammatory process in Parkinson's disease is a unique phenomenon.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10658622     DOI: 10.1016/s0306-4522(99)00455-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  92 in total

Review 1.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 2.  Atypical antiinflammatory activation of microglia induced by apoptotic neurons: possible role of phosphatidylserine-phosphatidylserine receptor interaction.

Authors:  Roberta De Simone; Maria Antonietta Ajmone-Cat; Luisa Minghetti
Journal:  Mol Neurobiol       Date:  2004-04       Impact factor: 5.590

Review 3.  Role of glial cells in neurotoxin-induced animal models of Parkinson's disease.

Authors:  Hironori Yokoyama; Hiroto Uchida; Hayato Kuroiwa; Jiro Kasahara; Tsutomu Araki
Journal:  Neurol Sci       Date:  2010-11-24       Impact factor: 3.307

Review 4.  Role of astrocytes in brain function and disease.

Authors:  Marta Sidoryk-Wegrzynowicz; Michal Wegrzynowicz; Eunsook Lee; Aaron B Bowman; Michael Aschner
Journal:  Toxicol Pathol       Date:  2010-11-12       Impact factor: 1.902

Review 5.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

6.  Curcumin protects dopaminergic neurons against inflammation-mediated damage and improves motor dysfunction induced by single intranigral lipopolysaccharide injection.

Authors:  Neha Sharma; Sheetal Sharma; Bimla Nehru
Journal:  Inflammopharmacology       Date:  2017-04-13       Impact factor: 4.473

7.  Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease.

Authors:  R Lee Mosley; Eric J Benner; Irena Kadiu; Mark Thomas; Michael D Boska; Khader Hasan; Chad Laurie; Howard E Gendelman
Journal:  Clin Neurosci Res       Date:  2006-12-06

Review 8.  Immune problems in central nervous system cell therapy.

Authors:  Roger A Barker; Håkan Widner
Journal:  NeuroRx       Date:  2004-10

9.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

10.  A cross-study transcriptional analysis of Parkinson's disease.

Authors:  Greg T Sutherland; Nicholas A Matigian; Alistair M Chalk; Matthew J Anderson; Peter A Silburn; Alan Mackay-Sim; Christine A Wells; George D Mellick
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.